Should fluoroquinolones be feared during pregnancy and breastfeeding?
Copyright © 2022 Elsevier Masson SAS. All rights reserved..
Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin) are antibiotics which pharmacological and therapeutic advantages resulted in a large use, now restricted because of resistances emergence and adverse effect risk. For pregnant or breastfeeding women they still are a cause of concern, based on the joint toxicity described in children directly treated, thus limiting their use in these populations. However, the data about exposed pregnancies published over time have not so far confirm these fears and allow, when a fluoroquinolone is clearly indicated, not to deprive pregnant patients of the therapeutic benefit of these important antibiotics and to envisage their use whatever the term of the pregnancy, within the current scope of their prescription. During breastfeeding the use of some of them can be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Gynecologie, obstetrique, fertilite & senologie - 50(2022), 12 vom: 25. Dez., Seite 807-809 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Faut-il craindre les fluoroquinolones chez une femme enceinte ou qui allaite ? |
|---|
| Beteiligte Personen: |
Vauzelle, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6GNT3Y5LMF |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 02.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gofs.2022.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349484732 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349484732 | ||
| 003 | DE-627 | ||
| 005 | 20231226042732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.gofs.2022.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349484732 | ||
| 035 | |a (NLM)36435563 | ||
| 035 | |a (PII)S2468-7189(22)00320-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Vauzelle, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Should fluoroquinolones be feared during pregnancy and breastfeeding? |
| 246 | 3 | 3 | |a Faut-il craindre les fluoroquinolones chez une femme enceinte ou qui allaite ? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 02.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin) are antibiotics which pharmacological and therapeutic advantages resulted in a large use, now restricted because of resistances emergence and adverse effect risk. For pregnant or breastfeeding women they still are a cause of concern, based on the joint toxicity described in children directly treated, thus limiting their use in these populations. However, the data about exposed pregnancies published over time have not so far confirm these fears and allow, when a fluoroquinolone is clearly indicated, not to deprive pregnant patients of the therapeutic benefit of these important antibiotics and to envisage their use whatever the term of the pregnancy, within the current scope of their prescription. During breastfeeding the use of some of them can be considered | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allaitement | |
| 650 | 4 | |a Breastfeeding | |
| 650 | 4 | |a Ciprofloxacin | |
| 650 | 4 | |a Ciprofloxacine | |
| 650 | 4 | |a Fluoroquinolones | |
| 650 | 4 | |a Grossesse | |
| 650 | 4 | |a Levofloxacin | |
| 650 | 4 | |a Lévofloxacine | |
| 650 | 4 | |a Pregnancy | |
| 650 | 7 | |a Fluoroquinolones |2 NLM | |
| 650 | 7 | |a Levofloxacin |2 NLM | |
| 650 | 7 | |a 6GNT3Y5LMF |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecologie, obstetrique, fertilite & senologie |d 2017 |g 50(2022), 12 vom: 25. Dez., Seite 807-809 |w (DE-627)NLM269302743 |x 2468-7189 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2022 |g number:12 |g day:25 |g month:12 |g pages:807-809 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gofs.2022.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2022 |e 12 |b 25 |c 12 |h 807-809 | ||